Selective TLR8 Modulator Compounds With Reduced Off-Target Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel modulators of toll-like receptors, particularly TLR8, that are potent and selective with reduced potential for off-target liabilities to treat a wide array of diseases including autoimmunity, inflammation, allergy, asthma, graft rejection, graft versus host disease, infection, cancer, and immunodeficiency.
Innovation Solution
Development of compounds of Formula I and their pharmaceutically acceptable salts, which modulate TLR8, and can be administered alone or with additional therapeutic agents to treat or prevent conditions responsive to TLR8 modulation, including hepatitis B and HIV infections, and hyperproliferative diseases like cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing TLR8 agonists are used to stimulate immune responses, then therapeutic benefit is achieved in various conditions, but off-target liabilities increase
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (Formula I) that target TLR8 with high selectivity. The molecular structure includes specific substituents (R1-R6, RZ groups) that are optimized to interact with TLR8 binding sites while avoiding off-target receptors, thereby achieving localized therapeutic action with minimal side effects.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters (substituent types, positions, and configurations in Formula I) to optimize TLR8 selectivity. By adjusting molecular weight, lipophilicity, and structural configuration, the compounds achieve enhanced potency and selectivity for TLR8 while reducing off-target effects.
2Reliability
If potent TLR8 modulators are developed to treat diseases, then disease treatment efficacy is improved, but molecular complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the TLR8 modulator into distinct functional modules in Formula I: a core heterocyclic structure, substituent groups (R1-R6), and optional stereochemical elements. This modular design allows systematic optimization of potency and selectivity while maintaining a manageable molecular framework that can be synthesized and characterized efficiently.
3Reliability
If selective TLR8 agonists are used to activate immune cells, then immune response is enhanced, but risk of inflammation increases
Solution Approach 1:
The patent employs the intermediary principle by designing compounds that act as selective mediators between the immune system and pathological conditions. The TLR8 modulators (Formula I) specifically activate TLR8-expressing cells (plasmacytoid dendritic cells, B cells) to produce desired immune responses while the selective mechanism prevents excessive or inappropriate activation that could lead to harmful inflammation.
Data Source
AI summary
This application relates generally to toll like receptor modulator compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR8), and methods of making and using them.